Last reviewed · How we verify
Met DR
At a glance
| Generic name | Met DR |
|---|---|
| Also known as | EFB0027 |
| Sponsor | Elcelyx Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- VCOM Pain Free Research Collaborative (NA)
- Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis (NA)
- Middle School Cluster Randomized Controlled Trial (RCT) to Evaluate E-Cigarette Prevention Program: CATCH My Breath (NA)
- Prolonged Daily Fasting as a Viable Alternative to Caloric Restriction in At-Risk Obese Humans (NA)
- Nurse-led Mind-body Intervention on Sexual Health for Breast Cancer Survivors (NA)
- Project SHINE (Sleep Health INitiative for Equity): Culturally Informing a Sleep Extension Intervention for African American Adults (PHASE1, PHASE2)
- Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) (NA)
- Laughter Yoga's Impact on Parental Stress, Burnout, and Self-Efficacy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Met DR CI brief — competitive landscape report
- Met DR updates RSS · CI watch RSS
- Elcelyx Therapeutics, Inc. portfolio CI